Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China.
Tao LiWen-Yu YangTing-Ting LiuYao LiLu LiuXuan ZhengLei ZhaoFan ZhangYi HuPublished in: Technology in cancer research & treatment (2023)
In the era of precision medicine, with the deepening of the research on malignant tumor driving genes, clinical oncology has fully entered the era of targeted therapy. For non-small-cell lung cancer (NSCLC), the development of targeted drugs targeting driver genes, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), has successfully opened up a new model of targeted therapy. At present, proto-oncogene rearranged during transfection (RET) fusion gene is an important novel oncogenic driving target, and specific receptor tyrosine kinase inhibitors (TKIs) targeting RET fusion have been approved. This article will review the latest research about the molecular characteristics, pathogenesis, detection, and clinical treatment strategies of RET rearrangements especially in China.
Keyphrases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- tyrosine kinase
- cancer therapy
- small cell lung cancer
- genome wide
- genome wide identification
- drug delivery
- transcription factor
- palliative care
- copy number
- bioinformatics analysis
- protein kinase
- label free
- single molecule
- real time pcr
- drug administration
- loop mediated isothermal amplification